CytoDyn (CYDY) Gross Margin (2021)

CytoDyn (CYDY) posted Gross Margin of 76.89% for Q4 2021, down 21.19% on a QoQ basis from 97.56% in Q3 2021.

CytoDyn (CYDY) Gross Margin (2021) Analysis & Trends

CytoDyn's Gross Margin history runs 1 years deep, the most recent figure standing at 76.89% for Q4 2021.

Quarterly Gross Margin changed N/A year-over-year to 76.89% in Q4 2021, while the trailing twelve-month figure through May 2022 was 71.0% (changed N/A YoY) and the FY2022 annual result came in at 71.0%, changed N/A from the prior year.
Gross Margin was 76.89% for Q4 2021 at CytoDyn, down from 97.56% in the prior quarter.
Across five years, Gross Margin topped out at 97.56% in Q3 2021 and bottomed at 76.89% in Q4 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	88.95%
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	86.85%
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	91.79%
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	90.68%
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	CytoDyn	258.22 Mn	258.22 Mn	-	-

Historic Data

Download Data

Date	Value
Nov 30, 2021	76.89%
Aug 31, 2021	97.56%